Group 1 - Akanda (NASDAQ:AKAN) stock is experiencing a significant rise with over 6.8 million shares traded, far exceeding its daily average of approximately 1.3 million shares and its float of 760,620 units [1] - The increase in trading volume occurs without any clear news or announcements from Akanda, including no press releases or SEC filings, and there is no analyst coverage contributing to the rally [1] - AKAN is classified as a penny stock, with a prior closing price of $1.45 and a market capitalization of $2.779 million [1] Group 2 - AKAN stock has risen by 34.1% as of Friday morning, but investors are advised to be cautious due to the lack of news and the sudden surge in trading volume, which may indicate a pump and dump scenario [2] - The current situation makes AKAN stock a risky investment, prompting investors to be careful about acquiring shares in the company [2]

Core Points - Akanda Corporation has completed sales of its securities under an existing Form F-3 shelf registration, raising approximately $4.98 million in gross proceeds since its effectiveness on January 29, 2024 [2][3]. - The company has maxed out its $5 million capacity under the F-3 shelf registration and will not raise further funds under this statement, indicating future offerings will require a new registration statement [3]. Company Overview - Akanda is an international medical cannabis and wellness platform focused on improving access to high-quality and affordable products [4]. - The company's portfolio includes CanMart, a UK-based licensed pharmaceutical importer and distributor, and partnerships with Cellen Life Sciences' Leva Clinic, a digital pain clinic in the UK [4]. - Akanda has acquired rights to develop a farming property in British Columbia for THC and cannabinoid (CBD) facilities [4].

Core Points - Akanda Corp has regained compliance with Nasdaq's Minimum Bid Price Requirement as of June 7, 2024, after meeting the necessary criteria for 10 consecutive business days [2][3]. Company Overview - Akanda Corp is an international medical cannabis company focused on improving access to high-quality and affordable products. Its portfolio includes CanMart, a licensed pharmaceutical importer and distributor in the UK, and partnerships with Cellen Life Sciences' Leva Clinic, a digital pain clinic [4]. - The company is also developing a Canadian farming property in British Columbia for THC and cannabinoid (CBD) production [4].

Akanda (NASDAQ:AKAN) stock is rocketing higher on Friday alongside heavy pre-market trading of the cannabis company’s shares.This has more than 6.3 million shares of AKAN stock changing hands as of this writing. That’s a massive increase over its daily average trading volume of about 590,000 shares.While there’s no news from Akanda today, the company did enact a reverse stock split yesterday. That saw it combine shares on a one-for-40 basis. The company enacted this reverse stock split to boost the price of ...

London, United Kingdom--(Newsfile Corp. - May 21, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, reported that it expects to implement a 1-for-40 reverse stock split on its ordinary shares effective May 23, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the ordinary shares will continue on The Nasdaq Capital Market under the symbol "AKAN". The new CUSIP number for the ordinary shares following the ...

Company Overview - Akanda Corp. is an international medical cannabis company focused on improving access to high-quality and affordable products [6] - The company's portfolio includes CanMart, a UK-based licensed pharmaceutical importer and distributor, and partnerships with Cellen Life Sciences' Leva Clinic, a digital pain clinic in the UK [6] Offering Details - Akanda has closed its second registered direct offering, selling 2,491,381 common shares at a price of $0.1031 and 12,057,600 pre-funded warrants at $0.103 per share [2] - The gross proceeds from this offering were approximately $1,500,000, which will be used for capital expenditures, operating capacity, working capital, general corporate purposes, and refinancing existing debt [3] Regulatory Compliance - The securities were offered under an effective shelf registration statement on Form F-3, which was declared effective on January 29, 2024 [4] - The final prospectus supplement related to the offering was filed with the SEC on May 20, 2024, and is available on the SEC's website [4]

Core Points - Akanda Corp has successfully closed a registered direct offering, selling 2,491,381 common shares at $0.1031 each and 21,756,922 pre-funded warrants at $0.103 each, generating gross proceeds of approximately $2,500,000 [2][3]. Group 1: Offering Details - The offering included 2,491,381 common shares and 21,756,922 pre-funded warrants, with the warrants being immediately exercisable at $0.0001 per share [2][3]. - The offering was conducted under an effective shelf registration statement filed with the SEC, which was declared effective on January 29, 2024 [4]. Group 2: Use of Proceeds - Akanda intends to utilize the net proceeds for capital expenditures, enhancing operating capacity, working capital, general corporate purposes, and refinancing or repaying existing debt [3]. Group 3: Company Overview - Akanda is an international medical cannabis company focused on improving access to high-quality and affordable products, with a portfolio that includes CanMart, a licensed pharmaceutical importer and distributor in the UK [6]. - The company is also developing a Canadian farming property in British Columbia for THC and cannabinoid (CBD) production [6].

Core Viewpoint - Akanda Corp. has announced a registered direct offering to raise approximately $2.5 million through the sale of common shares and pre-funded warrants, aimed at general working capital and corporate expenses [2][3]. Group 1: Offering Details - The offering includes 2,491,381 common shares priced at $0.1031 each and 21,756,922 pre-funded warrants at $0.103 per share, with the warrants being immediately exercisable at $0.0001 [2]. - The gross proceeds from the offering are estimated to be around $2,500,000 before deducting fees and expenses [3]. - The offering is expected to close on or about May 17, 2024, pending customary closing conditions [3]. Group 2: Regulatory Information - The offering is conducted under an effective shelf registration statement on Form F-3, previously filed with the SEC and effective since January 29, 2024 [4]. - A final prospectus related to the offering will be filed with the SEC and will be available for free on the SEC's website [4]. Group 3: Company Overview - Akanda Corp. is an international medical cannabis company focused on improving access to high-quality and affordable products [6]. - The company's portfolio includes CanMart, a licensed pharmaceutical importer and distributor in the UK, and partnerships with Cellen Life Sciences' Leva Clinic [6]. - Akanda is also developing a Canadian farming property in British Columbia for THC and CBD facilities [6].

Akanda Corp (NASDAQ: AKAN) is in focus this morning after receiving a notice of non-compliance from Nasdaq. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Akanda fails to satisfy the Nasdaq listing requirementsCopy link to sectionThe deficiency notification was issued to the international medical cannabis company because it failed to meet the “minimum stockholders’ equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1).  $AKAN failed to sa ...

Core Points - Akanda Corp. has received a deficiency notification from Nasdaq for non-compliance with the minimum stockholders' equity requirement of $2,500,000, as its reported stockholders' equity was ($3,828,892) for the fiscal year ended December 31, 2023 [2][3] - The company has 45 calendar days, until June 28, 2024, to submit a plan to regain compliance, with the possibility of an extension of up to 180 days if the plan is accepted [3] - Akanda is currently evaluating options to resolve the deficiency and intends to submit a comprehensive plan within the stipulated timeframe [3] - The company's common shares will continue to trade on the Nasdaq Capital Market under the symbol "AKAN" despite the notification [3] - Interim CEO Katie Field emphasized the company's commitment to addressing the compliance issue and appreciated investor support during this period [3] Company Overview - Akanda Corp. is an international medical cannabis and wellness platform company focused on improving access to high-quality and affordable products [4] - The company's portfolio includes CanMart, a UK-based licensed pharmaceutical importer and distributor, and partnerships with Cellen Life Sciences' Leva Clinic, a digital pain clinic in the UK [4] - Akanda has acquired rights to develop a Canadian farming property in British Columbia for THC and cannabinoid (CBD) facilities [4]